Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491 · EvoPAR-PR01 Phase 3Active, not recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 1,898 (actual)
- Start date
- 21 Nov 2023
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Apr 2031
- Last update posted
- 29 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Saruparib Drug
- Placebo Drug
- Abiraterone Acetate Drug
- Darolutamide Drug
- Enzalutamide Drug
Conditions and primary outcome
- Metastatic Castration-Sensitive Prostate Cancer
Primary outcome
Radiographic Progression-Free Survival (rPFS) (Up to approximately 50 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedSaruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
Future oncology (London, England) · 2026 Apr
PubMed 41979035 (opens in a new tab)DOI 10.1080/14796694.2026.2655433 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06120491 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.